Matuzumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Matuzumab" in English language version.

refsWebsite
Global rank English rank
4th place
4th place
2nd place
2nd place
5,225th place
4,062nd place
1,071st place
5,827th place
1st place
1st place
low place
low place
low place
low place

clinicaltrials.gov

doi.org

  • Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M (February 1987). "Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide". Archives of Biochemistry and Biophysics. 252 (2): 549–60. doi:10.1016/0003-9861(87)90062-2. PMID 2434025.
  • Leahy DJ (April 2008). "A molecular view of anti-ErbB monoclonal antibody therapy". Cancer Cell. 13 (4): 291–3. doi:10.1016/j.ccr.2008.03.010. PMID 18394550.
  • Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, et al. (May 2008). "Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425". Cancer Biology & Therapy. 7 (5): 726–33. doi:10.4161/cbt.7.5.6097. PMID 18424917.
  • Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. (January 2004). "Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor". Journal of Clinical Oncology. 22 (1): 175–84. doi:10.1200/JCO.2004.05.114. PMID 14701780.
  • Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, et al. (September 2008). "Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer". British Journal of Cancer. 99 (6): 868–74. doi:10.1038/sj.bjc.6604622. PMC 2538760. PMID 19238629.

n-tv.de

newsvz.de

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M (February 1987). "Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide". Archives of Biochemistry and Biophysics. 252 (2): 549–60. doi:10.1016/0003-9861(87)90062-2. PMID 2434025.
  • Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, et al. (July 1987). "Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects". Cancer Research. 47 (14): 3692–6. PMID 3297307.
  • Leahy DJ (April 2008). "A molecular view of anti-ErbB monoclonal antibody therapy". Cancer Cell. 13 (4): 291–3. doi:10.1016/j.ccr.2008.03.010. PMID 18394550.
  • Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, et al. (May 2008). "Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425". Cancer Biology & Therapy. 7 (5): 726–33. doi:10.4161/cbt.7.5.6097. PMID 18424917.
  • Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. (January 2004). "Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor". Journal of Clinical Oncology. 22 (1): 175–84. doi:10.1200/JCO.2004.05.114. PMID 14701780.
  • Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, et al. (September 2008). "Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer". British Journal of Cancer. 99 (6): 868–74. doi:10.1038/sj.bjc.6604622. PMC 2538760. PMID 19238629.

ncbi.nlm.nih.gov

takeda.com

web.archive.org